What is Theromics?
Founded in 2016 and headquartered in Massachusetts, Theromics specializes in radiofrequency and microwave medical device technology designed to optimize the ablation of lesions and soft tissue. The company's innovative approach targets critical areas in medical treatment, aiming to provide enhanced solutions for healthcare providers. This enterprise-level funding context suggests Theromics is moving beyond its initial development stages and is poised for significant scaling and market penetration.
How much funding has Theromics raised?
Theromics has raised a total of $2M across 2 funding rounds:
Debt
$15K
Angel/Seed
$2M
Debt (2021): $15K with participation from PPP
Angel/Seed (2022): $2M led by Maroon Venture Partners and Beacon Angels
Key Investors in Theromics
Maroon Venture Partners
Maroon Venture Partners is a venture fund that invests in early-stage companies associated with UMass Amherst, typically providing initial outside equity funding. The fund aims to support companies in achieving significant milestones towards commercial success.
Beacon Angels
Beacon Angels is an angel investment group that focuses on early-stage, fast-growing companies, investing between $50,000 and $400,000. The organization provides a platform for members to build portfolio value through shared capital and strategic relationships.
What's next for Theromics?
With a recent major strategic investment and a history of securing capital, Theromics is well-positioned for its next phase of expansion. The company's focus on advanced radiofrequency and microwave technology for medical ablations indicates a commitment to innovation within a specialized sector. Future endeavors will likely involve further product development, clinical validation, and market outreach to solidify its position against competitors and capitalize on the growing demand for effective soft tissue lesion treatments.
See full Theromics company page
